Allos Therapeutics, Inc has received notification from the US Food and Drug Administration (FDA) that the Oncologic Drugs Advisory Committee (ODAC) will hold a meeting on September 2, 2009, to review the company's New Drug Application (NDA) for pralatrexate for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
The details can be read here.
No comments:
Post a Comment